Tokyo, January 30, 2025 – Genesis Healthcare Co., Japan's pioneer in genetic testing integrates artificial intelligence with extensive genomic data to enhance understanding and applications in genetics. By offering solutions that scale the potential of Artificial General Gene Intelligence (AGGI), the company announces new leadership appointments to drive this vision forward.
President Appointment
On January 30th, 2025, Michel Mommejat, currently Chief Innovation Officer, was appointed to spearhead the company as the new President.
This appointment signifies a transformative milestone in the company's evolution, propelling its advancement into the next generation of genomics, with heightened focus on managing genomic big data and the utilization of artificial intelligence in genetics.
Michel Mommejat, who joined the company over six and a half years ago as Chief Marketing Officer before being promoted to Chief Innovation Officer, played a pivotal role in this transformation. He was instrumental in the development of GenesisGaia and the integration of AI into the company’s prediction models, products and services, successfully positioning Genesis Healthcare for sustainable, long-term growth.
This appointment marks the succession of leadership from the founders who have guided Genesis Healthcare Co. since its establishment 21 years ago. David Baran, President, will continue as a Board Director and Chairman.
Along with six external board member and auditors, Genesis Healthcare Co. remains committed to upholding corporate governance and external oversight to ensure the highest level of service for our shareholders and customers.
Appointment of Chief Commercial Officer
Genesis Healthcare Co. has named Shuichi Taniguchi as its Chief Commercial Officer. With over 25 years of experience in the biotech and bio-medical sectors, Shuichi Taniguchi has a strong track record of driving growth and forming strategic partnerships.
Michel Mommejat stated, “I extend my heartfelt congratulations to Shuichi Taniguchi on his well-earned promotion to Chief Commercial Officer. His leadership has been pivotal in driving the growth of GenesisPro, and with his expanded responsibilities, he will be instrumental in expanding our commercial presence and enhancing research collaborations across key sectors.
For press and media inquiries, please contact:
Email: press@genesis-healthcare.jp
About Genesis Healthcare Co.
Genesis Healthcare Co., Japan's pioneer in genetic testing integrates artificial intelligence with extensive genomic data to enhance understanding and applications in genetics. By offering solutions that scale the potential of Artificial General Gene Intelligence (AGGI), the company is in the forefront of advancing personalized health and precision medicine for medical, academic, governmental institutions, corporations, and individuals. Covering human, animal, and plant genetic sciences, Genesis Healthcare Co. provides comprehensive solutions, including testing, analysis, and AI-driven prediction models. Through its GenesisGaia AI platform, which hosts the largest genetic dataset of the Japanese population, the company envisions to accelerate drug development for numerous diseases that currently lack a cure.
For additional information, please visit:
GenesisGaia, GenesisPro, and GeneLife are registered trademarks of Genesis Healthcare Co.
コメント